| | | 1月6日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 三博脑科 | 不涉及脑机接口产品的研发、生产及销售 | | | 航天长峰 | 未实际开展脑机接口等相关业务 | | 项目投资 | 同飞股份 | 拟6亿元投资建设南方总部暨工业领域冷却设备及组件项目 | | 合同中标 | 精工钢构 | 中标杭州产创CBD76号地块项目 | | 股权转让 | 观想科技 | 拟购买辽晶电子100%股份 | | 回购 | 理工能科 | 累计回购3.59%股份 回购股份方案已实施完毕 | | 增减持 | 盛科通信 | 国家集成电路产业投资基金拟减持不超3.00%股份 | | 其他 | 浙江仙通 | 拟定增募资不超10.5亿元 投于研发中心升级建设项目等 | | | 利尔化学 | 预计2025年净利润同比增长113.62%-132.19% 写 簡屋に | 【热点】 三博脑科(301293.SZ)：不涉及脑机接口产品的研发、生产及销售 航天长峰(600855.SH)：未实际开展脑机接口等 相关业务 翔宇医疗(688626.SH)：在脑机接口方面的投入，相关产品尚 ...

停牌核查。 还有多只股票今日提示股价短期波动过大。 1月6日，中国卫星(600118.SH)公告称，公司股票自2025年12月3日以来累计上涨156.07%，明显高于同期行业及上证指数涨幅。公司基本面未发生重大变 化，存在市场情绪过热、非理性炒作风险。公司最新滚动市盈率和市净率显著高于行业平均水平，换手率也明显提高。公司提醒投资者注意二级市场交易 风险，理性决策。 锋龙股份(002931.SZ)公告称，公司股票自2025年12月25日至2026年1月6日连续7个交易日涨停，累计涨幅偏离值达到94.92%，显著偏离大盘指数，短期波 动幅度较大，已明显偏离市场走势，存在较高的炒作风险，如未来公司股票价格进一步异常上涨，公司可能申请停牌核查，投资者参与交易可能面临较大 风险。 三博脑科(301293.SZ)公告称，公司股票于2026年1月5日、1月6日连续两个交易日内收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动情形。公司 是以神经专科为特色的医疗服务集团，下属院区主要为患者提供以高精尖神经外科为主的综合医疗服务。公司目前不涉及脑机接口产品的研发、生产及销 售，神经调控技术带来的收入占公司营业收入比重很小， ...

Market Overview - The Shanghai Composite Index successfully maintained above the 4000-point mark, closing at 4083.67 points, marking a 13-day consecutive rise and reaching a ten-year closing high [1][3] - The market exhibited a broad-based rally with total trading volume exceeding 2.83 trillion yuan, and over 4100 stocks rising [1][3] Factors Supporting Market Growth - The upward trend of the Shanghai Index from 2700 points to 4000 points was supported by positive macroeconomic policies, economic recovery, and the influx of new capital [1][3] - The increase in margin trading balances and the recovery of public fund issuance contributed to market liquidity [3][5] Sector Performance - Strong performances were noted in sectors such as brain-computer interfaces, chemical engineering, large financial institutions, non-ferrous metals, commercial aerospace, autonomous driving, and semiconductors [3] - Conversely, sectors like beauty care, CPO, and banking showed relatively weaker performance [3] Historical Context - The Shanghai Index's breakthrough of 4000 points is rare, previously occurring only during two bull markets in May 2007 and April 2015 [4] - This current rally is characterized by a higher proportion of institutional investors and a focus on hard technology, high-end manufacturing, and new energy sectors [4] Future Market Outlook - Multiple market institutions anticipate a "spring rally" in January 2026, driven by favorable internal policies and liquidity conditions [5][6] - The macroeconomic policy cycle is expected to support a friendly liquidity environment, with significant capital inflows anticipated from institutional investors [5][6] - The current market is entering a "spring rally" phase, with a focus on structural opportunities in sectors like commercial aerospace, robotics, and petrochemicals [6]

1月5日，2026年A股第一个交易日，受到马斯克宣布脑机接口将量产消息的刺激，脑机接口概念板块多 只个股涨停，其中倍益康30cm涨停，三博脑科、翔宇医疗、美好医疗、爱朋医疗、诚益通等十余只个 股20cm涨停，南京熊猫、亿嘉和等个股10cm涨停。 收盘至晚间，多家上市公司开始密集披露脑机接口相关进展，进一步点燃市场热情。 首先是亿嘉和，其在收盘后披露2025年12月份投资者关系活动中的内容，表示公司积极探索包括"脑机 接口"在内的前沿技术与具身智能机器人技术融合，并表示已与麦澜德签署战略合作协议，旨在共同探 索"脑机接口+具身智能机器人"技术在智能康养等场景的应用可能性。 2026年开年，A股市场的首个交易日，脑机接口概念板块成为最亮眼的明星。 1月6日，该板块延续前一日的热度，倍益康、美好医疗、三博脑科、岩山科技、南京熊猫、创新医疗等 多股竞价涨停，伟思医疗、爱朋医疗、熵基科技、翔宇医疗等高开超10%。 这场资本狂欢的导火索，来自特斯拉创始人埃隆·马斯克在2025年12月31日发布的重磅消息。当天马斯 克在社交媒体上宣布，其脑机接口公司Neuralink将于2026年"大规模生产"其脑机接口产品。而十几天 前 ...

Core Viewpoint - Several companies are experiencing significant stock price fluctuations, leading to announcements of trading suspensions for further investigation to protect investor interests. Group 1: Company Announcements - Guosheng Technology (603778.SH) reported a cumulative stock price increase of 370.20% from October 31, 2025, to January 6, 2026, with a total market value nearing 14 billion yuan, prompting a trading suspension starting January 7, 2026 [1][9] - Jiamei Packaging announced a stock price increase of 230.48% from December 17, 2025, to January 6, 2026, leading to a trading suspension effective January 7, 2026, expected to last no more than three trading days [3][11] - China Satellite (600118.SH) noted a 156.07% stock price increase since December 3, 2025, significantly exceeding industry and index performance, indicating potential irrational market behavior [6][14] - Fenglong Co. (002931.SZ) experienced a 94.92% increase in stock price over seven consecutive trading days, leading to warnings about high speculation risks and potential trading suspension [6][14] - Sanbo Brain Science (301293.SZ) reported a cumulative price increase of over 30% over two trading days, classifying it as abnormal trading behavior, while clarifying its limited involvement in brain-machine interface products [7][15] Group 2: Market Risks - Companies are advising investors to be cautious of trading risks, including significant discrepancies in price-to-earnings and price-to-book ratios compared to industry averages, indicating potential for rapid price declines [5][13] - The overall market sentiment is characterized by excessive enthusiasm and irrational speculation, which could lead to abrupt corrections in stock prices [5][6]

停牌核查。 国晟科技(603778.SH)今日公告称，2025年10月31日至2026年1月6日期间，公司股票5次触及股价异常波动、1次触及严重异常波动情 形，其间累计涨幅高达370.20%，公司股价累计涨幅偏离基本面，存在市场情绪过热、非理性炒作风险，存在股价短期快速回落风险。 为维护广大投资者利益，公司将就上述股票交易波动情况进行核查。根据相关规定，经向上海证券交易所申请，公司股票将于2026年1月7 日（星期三）开市起停牌，自披露核查公告后复牌。 还有多只股票今日提示股价短期波动过大。 1月6日，中国卫星(600118.SH)公告称，公司股票自2025年12月3日以来累计上涨156.07%，明显高于同期行业及上证指数涨幅。公司基 本面未发生重大变化，存在市场情绪过热、非理性炒作风险。公司最新滚动市盈率和市净率显著高于行业平均水平，换手率也明显提高。 公司提醒投资者注意二级市场交易风险，理性决策。 锋龙股份(002931.SZ)公告称，公司股票自2025年12月25日至2026年1月6日连续7个交易日涨停，累计涨幅偏离值达到94.92%，显著偏 离大盘指数，短期波动幅度较大，已明显偏离市场走势，存在较高的 ...

2连板翔宇医疗：目前主要聚焦非侵入式脑机接口技术，截至2025年末相关产品尚未实现规模化销售 2连板伟思医疗：在脑机接口领域的新产品仍处于市场培育初期，尚未实现规模化销售 2连板麦澜德：在脑机接口领域的产品尚处于研发及市场培育期，尚未实现规模化销售 ►暂不涉及脑机接口业务 ►脑机接口业务进展 2连板三博脑科：目前不涉及脑机接口产品的研发、生产及销售 2连板航天长峰：目前公司未实际开展脑机接口等相关业务、不从事商业航天相关业务 ...

Core Insights - The A-share market has set two historical records on January 6, with the Shanghai Composite Index closing at 4083.67 points, marking a nearly ten-year high, and achieving a 13-day consecutive rise, breaking a 33-year record for the longest consecutive gains [1][3][6]. Market Performance - On January 6, all three major A-share indices rose, with the Shanghai Composite Index increasing by 1.50%, the Shenzhen Component Index by 1.4%, and the ChiNext Index by 0.75% [3]. - The trading volume reached 2.83 trillion yuan, indicating strong investor enthusiasm [1]. Sector Performance - The brain-computer interface sector saw a surge, with nearly 20 stocks hitting the daily limit [6]. - The commercial aerospace sector also performed well, with several stocks, including China Satellite Communications, reaching their daily limit [6]. - The non-ferrous metals sector was active, with companies like Luoyang Molybdenum and Zijin Mining hitting historical highs [6]. - Financial sectors, including insurance and securities, showed strong performance, with New China Life and China Pacific Insurance reaching new highs [6]. Fund Inflows - There is a strong expectation for fund inflows due to the "opening red" effect from financial institutions, with significant new premium funds available for market allocation [9][10]. - As of January 5, 2026, the financing balance reached 2.54 trillion yuan, a historical high, indicating increased market participation [9]. Market Outlook - Analysts predict a shift from valuation-driven to profit-driven market dynamics, with a more balanced market style expected in 2026 [11][12]. - The market is anticipated to maintain an upward trend supported by global liquidity easing and expectations of a stronger renminbi [10][12]. Investment Strategies - Investment firms suggest a balanced allocation strategy, focusing on sectors such as AI, resilient external demand, domestic consumption, and high dividend stocks [16]. - The "dumbbell strategy" is recommended, emphasizing growth sectors like technology and defensive sectors like non-ferrous metals and chemicals [16][17]. - Analysts advise against short-term trading and suggest focusing on long-term industry directions and value of dividend assets [17][19].

Core Insights - The brain-computer interface (BCI) industry is transitioning from "scientific experiments" to "commercialization," with Neuralink planning large-scale production by 2026, igniting market expectations [1] - China is accelerating its progress in the BCI field through supportive policies and technological breakthroughs, with significant investments being made in the sector [1][12] - The market is characterized as a "0 to 1" incremental market, driven by short-term sentiment from Neuralink's production expectations and favorable domestic policies [1] Investment Landscape - Strong Brain Technology recently completed approximately 2 billion yuan in financing, marking the second-largest funding round in the BCI sector after Neuralink [1] - Investors are advised to focus on companies with core technological advantages, such as self-developed chips and flexible electrodes, as well as those that can achieve commercial closure in rehabilitation and consumer electronics [1] Technology Comparison - The BCI technology landscape is divided into invasive, semi-invasive, and non-invasive routes, each with distinct differences in signal quality, safety, and commercialization timelines [2] - Invasive methods, like those used by Neuralink, involve surgical implantation of electrodes for high-resolution signal acquisition but come with high costs and long development cycles [5] - Non-invasive methods utilize external sensors for signal collection, offering lower costs and safety but facing challenges with signal attenuation [8] Competitive Landscape - The U.S. leads in invasive BCI technology by 2-5 years, while China is catching up, particularly in non-invasive applications where both countries are on par [9][11] - Chinese companies are making significant strides in clinical trials, with several achieving notable milestones in both invasive and non-invasive technologies [12] Company Developments - Companies like BrainCo and Huashan Hospital have completed pioneering clinical trials in invasive BCI systems, demonstrating the ability to control devices through thought [12][13] - Strong Brain Technology has received FDA and CE certifications, positioning itself as a leader in the commercialization of BCI products [12] - Other companies, such as Beijing Chip Intelligence and ZhiDian Medical, are also advancing in the invasive BCI space, with various clinical trials and product developments underway [13][14] Regulatory Environment - The Chinese government has included BCI in its national strategic emerging industries, with plans for independent billing standards and industry regulations to facilitate commercialization [11]

证券日报网讯 1月6日，三博脑科发布公告称，公司股票于2026年1月5日、1月6日，连续2个交易日内日 收盘价格涨幅偏离值累计超过30%，属于股票交易异常波动的情形。经核实，公司前期披露的信息不存 在需要更正、补充之处；近期公共传媒未报道与公司相关且市场关注度较高的信息；近期公司经营情况 及内外部经营环境未发生重大变化。 （编辑 任世碧） ...